Top

BMC Cancer

Published in:

Open Access 01-12-2023 | Gastric Cancer | Research

Effect of neoadjuvant chemotherapy combined with arterial chemoembolization on short-term clinical outcome of locally advanced gastric cancer

Authors: Jianguo Yang, Juncai Li, Qican Deng, Zhenzhou Chen, Kuan He, Yajun Chen, Zhongxue Fu

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

The purpose of this study was to explore the short-term efficacy and safety of neoadjuvant chemotherapy combined with arterial chemoembolization for locally advanced gastric cancer (LAGC).

Methods

We retrospectively analyzed the clinical data of 203 patients with LAGC who received neoadjuvant therapy from June 2019 to December 2021. The patients were divided into a neoadjuvant chemotherapy combined with arterial chemoembolization group (combined group, n = 102) and a neoadjuvant chemotherapy group (conventional group, n = 101). The adverse events of chemotherapy, postoperative complications and pathological complete response (pCR) rate were compared between the two groups. Univariate and multivariate analyses were performed to evaluate the potential factors affecting pCR.

Results

A total of 78.8% of the patients were in clinical stage III before neoadjuvant therapy. A total of 52.2% of the patients underwent surgery after receiving two cycles of neoadjuvant therapy. There were 21.2% patients with ≥ grade 3 (CTCAE 4.0) adverse events of chemotherapy and 11.3% patients with Clavien-Dindo classification ≥ grade 3 postoperative complications. Compared with the conventional group, the combination group did not experience an increase in the adverse events of chemotherapy or postoperative complications. The pCR rate in the combined group was significantly higher than that in the conventional group (16.7% vs. 4.95%, P = 0.012). The multivariate analysis showed that arterial chemoembolization, pre-treatment neutrophil-to-lymphocyte ratio (NLR) and pre-treatment platelet-to-lymphocyte ratio (PLR) were independent factors affecting pCR.

Conclusion

Neoadjuvant chemotherapy combined with arterial chemoembolization contributed to improving the pCR rate of LAGC patients. Arterial chemoembolization, pre-treatment NLR and pre-treatment PLR were also predictors of pCR.

Available only for authorised users

Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635–48. https://doi.org/10.1016/S0140-6736(20)31288-5.CrossRefPubMed

Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018;10:239–48. https://doi.org/10.2147/CMAR.S149619.CrossRefPubMedPubMedCentral

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Lordick F, Carneiro F, Cascinu S et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; S0923-7534(22)01851-8. doi: https://doi.org/10.1016/j.annonc.2022.07.004

Ajani JA, D’Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(2):167–92. https://doi.org/10.6004/jnccn.2022.0008.CrossRefPubMed

Yeh YS, Chen YT, Tsai HL, et al. Predictive value of ERCC1, ERCC2, and XRCC expression for patients with locally advanced or metastatic gastric Cancer treated with neoadjuvant mFOLFOX-4 Chemotherapy. Pathol Oncol Res. 2020;26(2):1105–16. https://doi.org/10.1007/s12253-019-00666-5.CrossRefPubMed

Wang Y, Li Z, Shan F, et al. Current status of diagnosis and treatment of early gastric cancer in China–Data from China gastrointestinal Cancer surgery union. Chin J Gastrointest Surg. 2018;21(2):168–74.

Matsuda T, Saika K. Cancer Burden in Japan based on the latest Cancer Statistics: need for evidence-based Cancer Control Programs. Ann Cancer Epidemiol. 2018;2:2. https://doi.org/10.21037/ace.2018.08.01.CrossRef

Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. https://doi.org/10.1056/NEJMoa055531.CrossRefPubMed

10.

Sano T, Coit DG, Kim HH, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer. 2017;20(2):217–25. https://doi.org/10.1007/s10120-016-0601-9.CrossRefPubMed

11.

Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: european Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28(35):5210–8. https://doi.org/10.1200/JCO.2009.26.6114.CrossRefPubMedPubMedCentral

12.

Kang YK, Yook JH, Park YK, et al. PRODIGY: a phase III study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 plus surgery and adjuvant S-1 Versus surgery and adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol. 2021;39(26):2903–13. https://doi.org/10.1200/JCO.20.02914.CrossRefPubMedPubMedCentral

13.

Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57. https://doi.org/10.1016/S0140-6736(18)32557-1.CrossRefPubMed

14.

Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):616–28. https://doi.org/10.1016/S1470-2045(18)30132-3.CrossRefPubMed

15.

Hofheinz RD, Hegewisch-Becker S, Kunzmann V, et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. Int J Cancer. 2021;149(6):1322–31. https://doi.org/10.1002/ijc.33696.CrossRefPubMed

16.

Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22(8):1081–92. https://doi.org/10.1016/S1470-2045(21)00297-7.CrossRefPubMed

17.

Galle PR, Tovoli F, Foerster F, et al. The treatment of intermediate stage tumours beyond TACE: from surgery to systemic therapy. J Hepatol. 2017;67(1):173–83. https://doi.org/10.1016/j.jhep.2017.03.007.CrossRefPubMed

18.

Wang J, Shi H, Yang G, et al. Combined intra-arterial and intravenous chemotherapy for unresectable, advanced gastric cancer has an improved curative effect compared with intravenous chemotherapy only. Oncol Lett. 2018;15(4):5662–70. https://doi.org/10.3892/ol.2018.8068.CrossRefPubMedPubMedCentral

19.

Zhang CW, Zou SC, Shi D, Zhao DJ. Clinical significance of preoperative regional intra-arterial infusion chemotherapy for advanced gastric cancer. World J Gastroenterol. 2004;10(20):3070–2. https://doi.org/10.3748/wjg.v10.i20.3070.CrossRefPubMedPubMedCentral

20.

Li M, Zhang J, Wang D, et al. A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer. Anticancer Drugs. 2009;20(10):941–5. https://doi.org/10.1097/CAD.0b013e328331af3a.CrossRefPubMed

21.

Shchepotin IB, Chorny V, Hanfelt J, Evans SR. Palliative superselective intra-arterial chemotherapy for advanced nonresectable gastric cancer. J Gastrointest Surg. 1999;3(4):426–31. https://doi.org/10.1016/s1091-255x. (99)80060-2.CrossRefPubMed

22.

Rausei S, Boni L, Rovera F, Dionigi G. Locally advanced gastric cancer: a new definition to standardise. J Clin Pathol. 2013;66(2):164–5. https://doi.org/10.1136/jclinpath-2012-201176.CrossRefPubMed

23.

Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9. https://doi.org/10.3322/caac.21388.CrossRefPubMed

24.

Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24(1):1–21. doi:https://doi.org/10.1007/s10120-020-01042-y

25.

Tomás TC, Eiriz I, Vitorino M, et al. Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer. World J Gastrointest Oncol. 2022;14(7):1307–23. https://doi.org/10.4251/wjgo.v14.i7.1307.CrossRefPubMedPubMedCentral

26.

Shi X, Zhao M, Shi B, et al. Pretreatment blood biomarkers combined with magnetic resonance imaging predict responses to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Front Oncol. 2022;12:916840. https://doi.org/10.3389/fonc.2022.916840.CrossRefPubMedPubMedCentral

27.

Seldinger SI. Catheter replacement of the needle in percutaneous arteriography. A new technique. Acta Radiol Suppl (Stockholm). 2008;434:47–52. https://doi.org/10.1080/02841850802133386.CrossRefPubMed

28.

Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19. https://doi.org/10.1007/s10120-016-0622-4.CrossRef

29.

Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13. https://doi.org/10.1097/01.sla.0000133083. 54934.ae.CrossRefPubMedPubMedCentral

30.

Jaffer AA, Thomas AD, David JB, editors. Gastric Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Springer International Publishing. American Joint Commission on Cancer; 2020.

31.

Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. https://doi.org/10.1038/s41572-020-00240-3.CrossRefPubMed

32.

Villanueva A, Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–62. https://doi.org/10.1056/NEJMra1713263.CrossRefPubMed

33.

Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14. https://doi.org/10.1016/S0140-6736(18)30010-2.CrossRefPubMed

34.

Nakajima T, Ota K, Ishihara S, et al. Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol. 1997;4(3):203–8. https://doi.org/10.1007/BF02306611.CrossRefPubMed

35.

Zhang C, Li G, Fan C, et al. Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer. World J Surg Oncol. 2012;10:162. https://doi.org/10.1186/1477-7819-10-162.CrossRefPubMedPubMedCentral

36.

Wan T, Zhang XF, Liang C, et al. The Prognostic Value of a pathologic complete response after Neoadjuvant Therapy for Digestive Cancer: systematic review and Meta-analysis of 21 studies. Ann Surg Oncol. 2019;26(5):1412–20. https://doi.org/10.1245/s10434-018-07147-0.CrossRefPubMed

37.

Li Z, Shan F, Wang Y, et al. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: a meta-analysis. PLoS ONE. 2018;13(1):e0189294. https://doi.org/10.1371/journal.pone.0189294.CrossRefPubMedPubMedCentral

38.

Kim HD, Lee JS, Park YS, et al. Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study. Gastric Cancer. 2022. https://doi.org/10.1007/s10120-022-01325-6.CrossRefPubMedPubMedCentral

39.

Becker K, Langer R, Reim D, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011;253(5):934–9. https://doi.org/10.1097/SLA.0b013e318216f449.CrossRefPubMed

40.

Zhu ZD, Pu YD. The study of pharmacokinetics of 5-Fu after left gastric artery intra-arterial infusion in treatment of gastric carcinoma. Chin J Bases Clin General Surg. 2001;8:26–8.

41.

Tao HQ, Zou SC. Effect of preoperative regional artery chemotherapy on proliferation and apoptosis of gastric carcinoma cells. World J Gastroenterol. 2002;8(3):451–4. https://doi.org/10.3748/wjg.v8.i3.451.CrossRefPubMedPubMedCentral

42.

Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–e503. https://doi.org/10.1016/S1470-2045(14)70263-3.CrossRefPubMed

43.

Greten FR, Grivennikov SI. Inflammation and Cancer: triggers, mechanisms, and Consequences. Immunity. 2019;51(1):27–41. https://doi.org/10.1016/j.immuni.2019.06.025.CrossRefPubMedPubMedCentral

44.

Dong J, Sun Q, Pan Y, Lu N, Han X, Zhou Q. Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy. BMC Cancer. 2021;21(1):700. https://doi.org/10.1186/s12885-021-08458-4.CrossRefPubMedPubMedCentral

45.

Dan J, Tan J, Huang J, et al. The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer. 2020;27(5):982–8. https://doi.org/10.1007/s12282-020-01096-x.CrossRefPubMed

46.

Corbeau I, Jacot W, Guiu S. Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast Cancer patients: a systematic review. Cancers (Basel). 2020;12(4):958. https://doi.org/10.3390/cancers12040958.CrossRefPubMed

47.

Braun LH, Baumann D, Zwirner K, et al. Neutrophil-to-lymphocyte ratio in rectal Cancer-Novel Biomarker of Tumor Immunogenicity during Radiotherapy or Confounding Variable? Int J Mol Sci. 2019;20(10):2448. https://doi.org/10.3390/ijms20102448.CrossRefPubMedPubMedCentral

48.

Jomrich G, Paireder M, Kristo I, et al. High systemic immune-inflammation index is an adverse prognostic factor for patients with gastroesophageal adenocarcinoma. Ann Surg. 2021;273(3):532–41. https://doi.org/10.1097/SLA.0000000000003370.CrossRefPubMed

49.

Gong W, Zhao L, Dong Z, et al. After neoadjuvant chemotherapy platelet/lymphocyte ratios negatively correlate with prognosis in gastric cancer patients. J Clin Lab Anal. 2018;32(5):e22364. https://doi.org/10.1002/jcla.22364.CrossRefPubMed

50.

Li Z, Li S, Ying X, et al. The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy. Gastric Cancer. 2020;23(3):540–9. https://doi.org/10.1007/s10120-019-01027-6.CrossRefPubMedPubMedCentral

51.

Wang SC, Chou JF, Strong VE, et al. Pre-treatment neutrophil to lymphocyte ratio independently predicts disease specific survival in resectable GE junction and gastric adenocarcinoma. Ann Surg. 2016;263:292–7. https://doi.org/10.1097/SLA.0000000000001189.CrossRefPubMed

52.

Galdiero MR, Marone G, Mantovani A. Cancer inflammation and cytokines. Cold Spring Harb Perspect Biol. 2018;10(8):a028662. https://doi.org/10.1101/cshperspect.a028662.CrossRefPubMedPubMedCentral

53.

Bald T, Quast T, Landsberg J, et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature. 2014;507(7490):109–13. https://doi.org/10.1038/nature13111.CrossRefPubMed

54.

Wada Y, Yoshida K, Tsutani Y, et al. Neutrophil elastase induces cell proliferation and migration by the release of TGF-alpha, PDGF and VEGF in esophageal cell lines. Oncol Rep. 2007;17(1):161–7.PubMed

55.

Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018;11(1):125. https://doi.org/10.1186/s13045-018-0669-2.CrossRefPubMedPubMedCentral

56.

Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576–90. https://doi.org/10.1016/j.ccr.2011.09.009.CrossRefPubMedPubMedCentral

57.

Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44. https://doi.org/10.1038/nature07205.CrossRefPubMed

58.

Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70. https://doi.org/10.1126/science.1203486.CrossRefPubMed

59.

Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1–50. https://doi.org/10.1016/S0065-2776(06)90001-7.CrossRefPubMed

60.

Bracale U, Corcione F, Pignata G, et al. Impact of neoadjuvant therapy followed by laparoscopic radical gastrectomy with D2 lymph node dissection in western population: a multi-institutional propensity score-matched study. J Surg Oncol. 2021;124(8):1338–46. https://doi.org/10.1002/jso.26657.CrossRefPubMedPubMedCentral

61.

Fujitani K, Ajani JA, Crane CH, et al. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol. 2007;14(7):2010–7. https://doi.org/10.1245/s10434-006-9198-2.CrossRefPubMed

62.

Balta S, Cakar M, Demirkol S, Arslan Z, Akhan M. Higher neutrophil to lymhocyte ratio in patients with metabolic syndrome. Clin Appl Thromb Hemost. 2013;19(5):579. https://doi.org/10.1177/1076029612475023.CrossRefPubMed

Title: Effect of neoadjuvant chemotherapy combined with arterial chemoembolization on short-term clinical outcome of locally advanced gastric cancer
Authors: Jianguo Yang
Juncai Li
Qican Deng
Zhenzhou Chen
Kuan He
Yajun Chen
Zhongxue Fu
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Gastric Cancer
Gastric Cancer
Cytostatic Therapy
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-10712-w

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Study of some potential biomarkers in Egyptian hepatitis C virus patients in relation to liver disease progression and HCC

SNHG1 opposes quiescence and promotes docetaxel sensitivity in prostate cancer

PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

Modified Naples prognostic score for evaluating the prognosis of patients with obstructive colorectal cancer